South San Francisco, CA, United States of America

Ulka Vijapurkar


 

Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 48(Granted Patents)


Location History:

  • Millbrae, CA (US) (2012)
  • South San Francisco, CA (US) (2013)

Company Filing History:


Years Active: 2012-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ulka Vijapurkar: Innovator in Cancer Treatment

Introduction

Ulka Vijapurkar is a notable inventor based in South San Francisco, CA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of phosphoinositide 3-kinase (PI3K) inhibitor compounds.

Latest Patents

Ulka Vijapurkar holds 2 patents that focus on combinations of PI3K inhibitor compounds and chemotherapeutic agents. His latest patents include methods of using these combinations for treating hyperproliferative disorders such as cancer. The patents detail the use of PI3K inhibitor compounds having specific formulas, including stereoisomers, geometric isomers, tautomers, metabolites, and pharmaceutically acceptable salts. These combinations are useful for in vitro, in situ, and in vivo diagnosis, prevention, or treatment of cancer and associated pathological conditions in mammalian cells.

Career Highlights

Throughout his career, Ulka Vijapurkar has worked with prominent companies in the pharmaceutical industry, including Genentech, Inc. and F. Hoffmann-La Roche AG. His work has significantly impacted the development of cancer therapies and has contributed to advancements in medical research.

Collaborations

Ulka has collaborated with several professionals in his field, including Marcia Belvin and Lori Friedman. These collaborations have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Ulka Vijapurkar's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the pharmaceutical industry. His work continues to pave the way for advancements in cancer therapies and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…